Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Research
Highly myopic eyes
Presbyopia
 
 
Survey

Do you use ocriplasmin to treat VMT in your practice?

Yes
9%
No
91%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


March 26, 2014
Reducing vision impairment risk
Certain lifestyle factors may reduce vision impairment risk
Physical activity and the occasional alcoholic libation may help decrease the risk of developing visual impairment, according to researchers from the University of Wisconsin School of Medicine and Public Health. More...
Bruch’s membrane thickness
Bruch's membrane thickness not related to axial length
Bruch's membrane thickness is not related to axial length in highly myopic eyes, and axially elongated eyes — despite having thinning of the sclera and choroid — have a normal Bruch’s membrane thickness. More...
Intracorneal inlay
No severe complications with presbyopia inlay
Implantation of an intracorneal inlay (Kamra, AcuFocus) modified the normal structure of the corneal layer of the eye but did not cause severe complications in a recent small study. More...
Product Profile
ZEISS Cataract Suite markerless
Align toric IOLs and skip the manual marking and data transfer steps with products designed to work together for markerless toric IOL alignment.
Read more
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: